The dynamics of thrombin formation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 1, 2003, Pages 17-25

  Mann, Kenneth G ^a   Butenas, Saulius ^a   Brummel, Kathleen ^a  

^a NONE

Author keywords

Aggregation; Coagulation; Coagulation inhibitors; Fibrinogen

Indexed keywords

ANTITHROMBIN III; APC PROTEIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING INHIBITOR; FIBRIN; FIBRINOGEN; PROTEIN C; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; LUNG EMBOLISM; MATHEMATICAL MODEL; MEMBRANE BINDING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SHORT SURVEY; STOICHIOMETRY; STROKE; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS;

ANIMALS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; HEMOSTASIS; HUMANS; MODELS, BIOLOGICAL; THROMBIN; THROMBOPLASTIN;

EID: 0037231552     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000046238.23903.FC     Document Type: Short Survey

References (99)

1. Jenny NS, Mann KG. Coagulation cascade: an overview. In: Loscalzo J, Schafer Al. eds. Thrombosis and Hemorrhage. Baltimore, Md: Williams and Wilkins; 1998:3-27.
2. Rosing J, van Rijn JLML, Bevers EM, van Dieijen G, Comfurius P, Zwaal RF. The role of activated human platelets in prothrombin and factor X activation. Blood. 1985;65:319-332.
3. Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood. 1991;77:2641-2648.
4. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta. 1983;736:57-66.
5. Mann KG, Bovill EG, Krishnaswamy S. Surface-dependent reactions in the propagation phase of blood coagulation. Ann N Y Acad Sci. 1991;614:63-75.
6. Krishnaswamy S, Field KA, Edgington TS, Morrissey JH, Mann KG. Role of the membrane surface in the activation of human coagulation factor X. J Biol Chem. 1992;267:26110-26120.
7. Smirnov MD, Ford DA, Esmon CT, Esmon NL. The effect of membrane composition on the hemostatic balance. Biochemistry. 1999;38:3591-3598.
8. Jesty J, Lorenz A, Rodriquez J, Wun T. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood. 1996;87:2301-2307.
9. van't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem. 1997:272:4367-4377.
10. van't Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. J Biol Chem. 1997;272:7983-7994.
11. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood. 1996;88:1583-1587.
12. Rosen ED, Chan JC, Idusogie E, Clotman F, Vlasuk G, Luther T, Jalbert LR, Albrecht S, Zhong L, Lissens A, Schoonjans L, Collen D, Castellino FJ, Carmeliet P. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature. 1997;390:290-294.
13. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature. 1996;384:66-68.
14. Huang ZF, Higuchi D, Lasky N, Broze GJ Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood. 1997:90:944-951.
15. Dewerchin M, Liang Z, Moons L, Carmeliet P, Castellino FJ, Collen D, Rosen ED. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice. Thromb Haemost. 2000;83:185-190.
16. Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K. Xiao Q. Bugge TH, Degen SJ. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci USA. 1998;95:7597-7602.
17. Jalbert LR, Rosen ED, Moons L, Chan JC, Carmeliet P, Collen D, Castellino FJ. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest. 1998;102:1481-1488.
18. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of hemophilia A. Nat Genet. 1995;10:119-121.
19. Kundu RK, Sangiorgi F, Wu LY, Kurachi K, Anderson WF, Maxson R, Gordon EM. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood. 1998;92:168-174.
20. O'Marcaigh AS, Nicols WL, Hassinger NL, Mullins JD, Mallouh AA, Gilchrist GS, Owen WG. Genetic analysis and functional characterization of prothrombins Corpus Christi (Arg382-Cys) Dhahran (Arg271-His), and hypoprothrombinemia. Blood. 1996;88:2611-2618.
21. Henriksen RA, Mann KG. Substitution of valine for glycine-558 in the congenital dysthrombin Quick II alters primary substrate specificity. Biochemistry 1989;28:2078-2082.
22. Bernardi F, Marchetti G, Patracchini P, Volinia S, Gemmati D, Simioni P, Girolami A. Partial gene deletion in a family with factor X deficiency. Blood. 1989;73:2123-2127.
23. Seeler RA. Parahemophilia. factor V deficiency. Med Clin North Am. 1972;56:119-125.
24. 359 Met mutation in factor VII of an individual with a hereditary deficiency causes defective secretion of the molecule. Blood. 1996;87:5085-5094.
25. Matsushita T, Kojima T, Emi N, Takahashi I, Saito H. Impaired human tissue factor-mediated in blood clotting factor VIINagoya (Arg304 224 Trp): evidence that a region in the catalytic domain of factor VII is important for the association with tissue factor. J Biol Chem. 1994;269:7355-7363.
26. al-Monhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol. 1994;46:343-347.
27. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1-8.
28. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81:734-744.
29. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA. 1999;96:2311-2315.
30. Osterud B. The role of platelets in decrypting monocyte tissue factor. Semin Hematol. 2001;38(4 suppl 12):2-5.
31. Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T, Oelschlagel U, Zahler S, Engelmann B. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun. 2001;281:603-609.
32. Santucci RA, Erlich J, Labriola J, Wilson M, Kao KJ, Kickler TS, Spillert C, Mackman N. Measurement of tissue factor activity in whole blood. Thromb Haemost. 2000;83:445-454.
33. Takahashi H, Satoh N, Wada K, Takakuwa E, Seki Y, Shibata A. Tissue factor in plasma of patients with disseminated intravascular coagulation. Am J Hematol. 1994;46:333-337.
34. Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry. 1996:35:1904-1910.
35. Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor Vlla: effects of calcium, phospholipids, and tissue factor. Biochemistry. 1990;29:9418-9425.
36. Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol. Chem. 1993;268:767-770.
37. Lawson JH, Butenas S, Mann KG. The evaluation of complex-dependent alterations in human factor VIIa. J Biol Chem. 1992;267:4834-4843.
38. Butenas S, Ribarik N, Mann KG. Synthetic substrates for human factor VIIa and factor VIIa-tissue factor. Biochemistry. 1993;32:6531-6538.
39. 2+, phospholipids and tissue factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J. 1990;265:327-336.
40. Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem. 1991;266:11317-11327.
41. Butenas S. van't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem. 1997;272:21527-21533.
42. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002;100:148-152.
43. Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood. 1989;74:1021-1024.
44. Ahmad SS, Rawala-Sheikh R, Walsh PN. Components and assembly of the factor X activating complex. Semin Thromb Hemost. 1992;18:311-323.
45. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 1993;222:525-559.
46. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor, Nature. 1989;338:518 -520.
47. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost. 1991;66:6-15.
48. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1982;257:859-864.
49. Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta. 1979;571:333-342.
50. Suzuki K, Stenflo J, Dahlback B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem. 1983;258:1914-1920.
51. Eaton D, Rodriquez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulation activity. Biochemistry. 1986;25:505-512.
52. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991;78:387-393.
53. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
54. Nesheim ME, Canfield WM, Kisiel W, Mann KG. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem. 1982;257:1443-1447.
55. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin, I: an empirical study. J Biol Chem. 1994;269:23357-23366.
56. LEIDEN. J Biol Chem. 1997;272:20721-20729.
57. LEIDEN. Blood. 1997;90:3067-3072.
58. van't Veer C, Butenas S, Golden NJ, Mann KG. Regulation of prothrombinase activity by protein S. Thromb Haemost. 1999;82:80-87,
59. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation, Blood, 1999;94:2169-2178.
60. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood. 2000;95:1330-1335.
61. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood. 1996;88:3432-3445.
62. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood. 1998;91:4581-4592.
63. Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem. 1999;274:22862-22870.
64. Butenas S, Branda RF, van't Veer C, Cawthern KM, Mann KG. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb. Haemost. 2001;86:660-667.
65. Holmes MB, Schneider DJ. Hayes MG, Sobel BE. Mann KG. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation.;2000;102:2051-2057,
66. Butenas S. Cawthern KM, van't Veer C, DiLorenzo ME, Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood. 2001;97:2314-2322.
67. , Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor Vlla-dependent coagulation in hemophilia blood. Blood. 2002;99:923-930.
68. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation. 2001;104:2311-2317.
69. Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. J Biol Chem. 1994;269:23367-23373.
70. Mann KG. How much factor V is enough? Thromb Haemost. 2000;83:3-4.
71. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002;277:18322-18333.
72. Undas A, Brummel KE, Musial J, Mann KG. Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103:2248-2253.
73. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood. 2001;98:2423-2431.
74. 3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001;104:2666-2672.
75. Undas A, Wojciech JS, Brummel KE, Musial J, Mann KG, Szczeklik A. Aspirin and cardioprotective effects of the Va?34Leu polymorphism of factor XIII. Circulation. In press.
76. Jenny RJ. Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA. 1987;84:4846-4850.
77. Suzuki K, Dahlback B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 1982;257:6556-6564.
78. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry. 1990;29:1118-1128.
79. Mann KG, Kalafatis M. Factor V. A combination of Dr. Jeckyll and Mr. Hyde. Blood. In press.
80. Matthews JM, Rizza CR. Clinical features of clotting factor deficiencies. In: Biggs R, Rizza CR, eds. Human Blood Coagulation, Haemostasis and Thrombosis. Oxford: Blackwell Scientific Publications; 1984:119-169.
81. Bolton-Maggs PHB. Factor XI deficiency. Baillieres Clin Hematol. 1996;9:355-368.
82. Ragni MV, Sinha D, Seaman F, Lewis JH, Spero JA, Walsh PN. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood. 1985;65:719-724.
83. Seligsohn U. Factor XI deficiency. Thromb Haemost. 1993;70:68-71.
84. Lipscomb MS, Walsh PN. Human platelets and factor XI. Localization in platelet membranes of factor XI-like activity and its functional distinction from plasma factor XI. J Clin Invest. 1979;63:1006-1014.
85. Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. Science. 1991;253:909-912.
86. Keularts IMLW, Zivelin A, Seligsohn U, Hemker HC, Beguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost. 2001;85:1060-1065.
87. Tracy PB, Eide LL, Bowie EJ, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982;60:59-63.
88. Kane WH, Lindhout MJ, Jackson CM, Majerus PW. Factor Va-dependent binding of factor Xa to human platelets. J Biol Chem. 1980;255:662-669.
89. Chesney CM, Pifer D, Colman RW. Subcellular localization and secretion of factor V from human platelets. Proc Natl Acad Sci U S A. 1981;78:5180-5184.
90. Walsh PN. Factor XI. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles & Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:191-202.
91. Hu CJ, Baglia FA, Mills DC, Konkle BA, Walsh PN. Tissue-specific expression of functional platelet factor XI is independent of plasma factor XI expression. Blood. 1998;91:3800-3807.
92. Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendorn H, Rivard GE. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet factor V deficiency. J Clin Invest. 1984;74:1221-1228.
93. Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol. 1992;29:177-188.
94. Blomback B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogenfibrin transition in blood coagulation. Nature. 1978;275:501-505.
95. Lorand L, Chenoweth D, Domanik RA. Chain pairs in the crosslinking of fibrin. Biochem Biophys Res Commun. 1969;37:219-224.
96. Doolittle RF, Yang Z, Mochalkin I. Crystal structure studies on fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:31-43.
97. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-14484.
98. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem. 1996;271:16603-16608.
99. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176-27181.